[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 13 of about 13
1. Tiseo M, Martelli O, Mancuso A, Sormani MP, Bruzzi P, Di Salvia R, De Marinis F, Ardizzoni A: Short hydration regimen and nephrotoxicity of intermediate to high-dose cisplatin-based chemotherapy for outpatient treatment in lung cancer and mesothelioma. Tumori; 2007 Mar-Apr;93(2):138-44
Hazardous Substances Data Bank. SODIUM CHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Short hydration regimen and nephrotoxicity of intermediate to high-dose cisplatin-based chemotherapy for outpatient treatment in lung cancer and mesothelioma.
  • AIMS AND BACKGROUND: Cisplatin, a standard component of combination chemotherapy for several tumors, presents important anti-tumor properties but also several toxic effects.
  • In several countries, to reduce nephrotoxicity after cisplatin administration, a 24-h hydration is recommended following a chemotherapy treatment in a hospital regimen.
  • In our Institutions, cisplatin chemotherapy is an outpatient treatment that provides adequate hydration with an NaCl solution plus furosemide and diuresis monitoring during treatment.
  • METHODS AND STUDY DESIGN: To assess incidence of cisplatin nephrotoxicity using a short hydration regimen, which included 2000 ml of fluids with control of diuresis, individual outpatient data was pooled retrospectively from patients enrolled in large randomized studies regarding cisplatin-based chemotherapy in lung cancer and mesothelioma.
  • RESULTS: Five patients out of 107 (4.6%) were withdrawn from chemotherapy because of renal toxicity.
  • For the other 102 patients, serum creatinine and creatinine clearance measurements were stable around the normal values during treatment.
  • No time trends relating to serum creatinine levels or creatinine clearance and cycle numbers or cisplatin-cumulative doses were detected (P = 0.36 and P = 0.64, for the relationship with cycle number, and P = 0.39 and P = 0.65 for the relationship with cumulative dose, respectively, random effect model) after adjusting for the total number of cycles administered.
  • CONCLUSIONS: These observations indicate that intermediate to high-dose cisplatin administration is feasible in outpatient management with a short hydration regimen without high risk of nephrotoxicity.
  • [MeSH-major] Cisplatin / administration & dosage. Fluid Therapy / methods. Kidney Diseases / chemically induced. Lung Neoplasms / drug therapy. Mesothelioma / drug therapy
  • [MeSH-minor] Adult. Aged. Ambulatory Care. Antineoplastic Agents / therapeutic use. Antineoplastic Agents / toxicity. Creatine / blood. Female. Furosemide / therapeutic use. Humans. Incidence. Male. Middle Aged. Randomized Controlled Trials as Topic. Retrospective Studies. Sodium Chloride / therapeutic use


2. Mujoomdar AA, Tilleman TR, Richards WG, Bueno R, Sugarbaker DJ: Prevalence of in vitro chemotherapeutic drug resistance in primary malignant pleural mesothelioma: result in a cohort of 203 resection specimens. J Thorac Cardiovasc Surg; 2010 Aug;140(2):352-5
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence of in vitro chemotherapeutic drug resistance in primary malignant pleural mesothelioma: result in a cohort of 203 resection specimens.
  • OBJECTIVE: Optimizing the multimodality treatment of malignant pleural mesothelioma depends on many factors including an adequate chemotherapeutic response.
  • Currently, chemotherapy regimens for patients with mesothelioma are empirically selected.
  • In vitro chemotherapy resistance in human mesothelioma has not been reported.
  • Our goal was to determine the prevalence of drug resistance in a large sample of malignant pleural mesothelioma using a commercially available assay.
  • METHODS: Tumors specimens (n = 203) were cultured for analysis of chemoresistance using the extreme drug resistance assay.
  • Each specimen was tested with 3 drugs: cisplatin, gemcitabine, and vinorelbine.
  • Drug resistance was characterized as low, intermediate, or extreme.
  • Forty-four (26%) patients received neoadjuvant chemotherapy before sampling and testing.
  • The distribution of histopathologic cell types was epithelial (103; 61%), mixed (57; 34%), and sarcomatoid (8; 5%).
  • RESULTS: A significant proportion of tumors had extreme/intermediate drug resistance to cisplatin (27%), gemcitabine (31%), or vinorelbine (59%).
  • Nineteen tumors (11%) had extreme/intermediate resistance to all 3 drugs.
  • Resistance (extreme/intermediate) to cisplatin was more prevalent in epithelial tumors than in nonepithelial (33% vs 18%; P = .0394).
  • No significant differences in chemoresistance were found in tumors of patients who had received neoadjuvant chemotherapy compared with those who had not.
  • CONCLUSIONS: The feasibility of performing off-site in vitro drug resistance assays on resected malignant mesothelioma specimens is reported.
  • A significant proportion of mesothelioma tumors exhibited extreme/intermediate resistance to cisplatin, gemcitabine, or vinorelbine.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Cell Proliferation / drug effects. Cisplatin / pharmacology. Deoxycytidine / analogs & derivatives. Drug Resistance, Neoplasm. Drug Screening Assays, Antitumor. Mesothelioma / drug therapy. Pleural Neoplasms / drug therapy. Vinblastine / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Cohort Studies. Feasibility Studies. Humans. Middle Aged. Neoadjuvant Therapy. Patient Selection. Time Factors. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20653100.001).
  • [ISSN] 1097-685X
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0W860991D6 / Deoxycytidine; 5V9KLZ54CY / Vinblastine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


3. Ryan DP, Supko JG, Eder JP, Seiden MV, Demetri G, Lynch TJ, Fischman AJ, Davis J, Jimeno J, Clark JW: Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies. Clin Cancer Res; 2001 Feb;7(2):231-42
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The in vitro chemosensitivity of cancer cells to ET-743 is markedly enhanced by prolonging the duration of exposure to the drug.
  • (d) Eastern Cooperative Oncology Group performance status < or = 1, 20 patients; and (e) two prior regimens of chemotherapy, 7 patients.
  • Reversible grade 4 transaminitis occurred in two of nine patients after treatment with the first cycle of therapy at the third dose level of 1200 microg/m2.
  • Another patient experienced grade 4 rhabdomyolysis, renal failure requiring hemodialysis, grade 4 neutropenia, and grade 3 thrombocytopenia during the second cycle of therapy with this dose.
  • The maximum tolerated dose was 1200 microg/m2, and an additional six patients were enrolled at an intermediate dose level of 1050 microg/m2.
  • Toxicity of the drug is clearly schedule-dependent, because increasing the duration of infusion from 3 or 24 h to 72 h results in decreased myelosuppression and comparable hepatotoxicity.
  • Although there were no objective responses to therapy, clear evidence of antitumor activity was observed in a patient with epithelioid mesothelioma, as confirmed by positron emission tomography studies.
  • The therapeutically optimal administration schedule remains to be established, inasmuch as there have been indications of activity against a variety of tumors during Phase I studies when the drug was infused over times ranging from 1 to 72 h.
  • Characterizing the pharmacokinetics of ET-743 during the course of Phase II trials and Phase I combination studies is recommended to assure that this promising new anticancer drug can be used with an acceptable margin of safety.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Alanine Transaminase / metabolism. Area Under Curve. Aspartate Aminotransferases / metabolism. Dose-Response Relationship, Drug. Female. Humans. Infusions, Intravenous. Liver / drug effects. Male. Maximum Tolerated Dose. Middle Aged. Models, Chemical. Tetrahydroisoquinolines. Time Factors. Toxicity Tests

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11234874.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Dioxoles; 0 / Isoquinolines; 0 / Tetrahydroisoquinolines; 114899-77-3 / trabectedin; EC 2.6.1.1 / Aspartate Aminotransferases; EC 2.6.1.2 / Alanine Transaminase
  •  go-up   go-down


Advertisement
4. Hedges KL, Morré DM, Wu LY, Morre DJ: Adriamycin tolerance in human mesothelioma lines and cell surface NADH oxidase. Life Sci; 2003 Jul 18;73(9):1189-98
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adriamycin tolerance in human mesothelioma lines and cell surface NADH oxidase.
  • Adriamycin tolerant human mesothelioma cell lines derived from a single tumor prior to either chemotherapy or radiation therapy and a susceptible cell line were investigated.
  • Not only was growth resistant to low doses of adriamycin but an unusual pattern of resistance was encountered in which cells seemed to better tolerate high adriamycin doses than intermediate doses.
  • The findings suggest a relationship between the growth response to adriamycin of the adriamycin tolerant mesothelioma lines and the activity of the plasma membrane-associated NADH oxidase activity of the cell surface in these cell lines.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Doxorubicin / pharmacology. Drug Tolerance. Mesothelioma / drug therapy. Multienzyme Complexes / metabolism. NADH, NADPH Oxidoreductases / metabolism
  • [MeSH-minor] Cell Membrane / drug effects. Cell Membrane / enzymology. Dose-Response Relationship, Drug. Drug Screening Assays, Antitumor. Humans. Tumor Cells, Cultured / drug effects. Tumor Cells, Cultured / metabolism

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12818726.001).
  • [ISSN] 0024-3205
  • [Journal-full-title] Life sciences
  • [ISO-abbreviation] Life Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Multienzyme Complexes; 80168379AG / Doxorubicin; EC 1.6.- / NADH oxidase; EC 1.6.- / NADH, NADPH Oxidoreductases
  • [Keywords] NASA ; Non-programmatic
  •  go-up   go-down


5. Sethna K, Mohamed F, Marchettini P, Elias D, Sugarbaker PH: Peritoneal cystic mesothelioma: a case series. Tumori; 2003 Jan-Feb;89(1):31-5
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for peritoneal cystic mesothelioma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritoneal cystic mesothelioma: a case series.
  • BACKGROUND: Cystic peritoneal mesothelioma is a rare disease associated with a favorable short-term prognosis.
  • Longer follow-up documenting a persistence of symptoms and a high rate of recurrence after debulking surgery along with an uncertain natural history prompt a re-evaluation of prior treatment recommendations.
  • METHODS: The experience with five cases of cystic peritoneal mesothelioma, four females and one male, are reviewed.
  • All of these patients were treated with cytoreductive surgery with peritonectomy procedures and heated intraoperative intraperitoneal chemotherapy.
  • CT, pathology and current status were investigated in order to learn more about the natural history of this disease.
  • Her prognosis for long-term survival is guarded because of mesothelioma extension into the chest.
  • Disease control of both ascites and pain in the abdomen and pelvis was achieved in all five patients treated with cytoreductive surgery plus intraperitoneal chemotherapy.
  • CONCLUSIONS: Cystic peritoneal mesothelioma should no longer be referred to as "benign" cystic mesothelioma.
  • An aggressive approach with complete disease eradication is the correct goal of treatment.
  • From our experience, cytoreductive surgery to remove all visible tumor and intraperitoneal chemotherapy to control microscopic residual disease will help patients with peritoneal cystic mesothelioma to remain symptom- and disease-free over an extended time period with a single surgical intervention.
  • Disease eradication may prevent the transition to an aggressive and fatal disease process.
  • [MeSH-major] Mesothelioma, Cystic. Peritoneal Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12729358.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 16
  •  go-up   go-down


6. Opitz I, Sigrist B, Hillinger S, Lardinois D, Stahel R, Weder W, Hopkins-Donaldson S: Taurolidine and povidone-iodine induce different types of cell death in malignant pleural mesothelioma. Lung Cancer; 2007 Jun;56(3):327-36
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Taurolidine and povidone-iodine induce different types of cell death in malignant pleural mesothelioma.
  • The type of cell death induced in malignant pleural mesothelioma (MPM) cell lines by these agents was compared, and their ability to sensitize to chemotherapy assessed.
  • Both taurolidine and PVP-I inhibited MPM cell growth after 7.5min incubation, but taurolidine was more effective at later time points and was more specific towards tumour cells than PVP-I.
  • Taurolidine but not PVP-I treatment resulted in p53 activation in 2/3 MPM cell lines and a decrease in the protein levels of survivin, Bcl-2 and Mcl-1.
  • Survivin also decreased in response to PVP-I whereas Bcl-xL remained unaffected by both treatments.
  • Targeting of Bcl-xL with siRNA sensitized MPM cells to taurolidine and taurolidine treatment sensitized MPM cells to cisplatin-induced apoptosis.
  • In conclusion, taurolidine and PVP-I are both cytotoxic to human MPM cells at early and late time points and induce reactive oxygen intermediate production.
  • Both agents are promising candidates for use in local treatment within multimodality concepts for MPM.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cell Death / drug effects. Mesothelioma / pathology. Pleural Neoplasms / pathology. Povidone-Iodine / therapeutic use. Taurine / analogs & derivatives. Thiadiazines / therapeutic use
  • [MeSH-minor] Anti-Infective Agents, Local. Biopsy. Blotting, Western. Caspase 3 / drug effects. Caspase 3 / metabolism. Cell Line, Tumor. Cell Membrane Permeability / drug effects. Cell Proliferation / drug effects. Cell Survival / drug effects. Cisplatin / therapeutic use. Drug Therapy, Combination. Enzyme Activation / drug effects. Flow Cytometry. Gene Expression Regulation, Neoplastic / drug effects. Genes, p53 / drug effects. Genes, p53 / genetics. Humans. Mitochondrial Membranes / drug effects. Mitochondrial Membranes / metabolism. Reactive Oxygen Species / agonists. Reactive Oxygen Species / metabolism


7. Sugarbaker PH: Cytoreductive surgery and peri-operative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome. Eur J Surg Oncol; 2001 Apr;27(3):239-43
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoreductive surgery and peri-operative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome.
  • Peritoneal carcinomatosis, regardless of primary tumour type, has always been a lethal condition.
  • Recently special treatments using cytoreductive surgery with peritonectomy procedures combined with peri-operative intraperitoneal chemotherapy have resulted in long-term survival.
  • Pseudomyxoma peritonei may be especially appropriate for these aggressive local regional treatments.
  • All patients treated prior to 1999 are presented; patients left with gross residual disease after surgery were not given intraperitoneal chemotherapy, but were later treated with intravenous chemotherapy after cytoreduction.
  • The intraperitoneal chemotherapy was given in the peri-operative period, starting with mitomycin C.
  • For patients whose pathology showed adenomucinosis, intraperitoneal chemotherapy was limited to treatment in the operating theatre with heated mitomycin C.
  • The histopathology categorized the patients as adenomucinosis, intermediate type, or mucinous carcinomatosis.
  • Patients with a complete cytoreduction and adenomucinosis by pathology had a 5-year survival of 86%; while hybrid pathology survival at 5 years was 50%.
  • Cytoreductive surgery and peri-operative intraperitoneal chemotherapy is the current standard treatment for selected patients with peritoneal surface spread of appendiceal primary tumours.
  • Similar strategies for other patients with peritoneal surface malignancy such as peritoneal carcinomatosis from colon or gastric cancer, peritoneal sarcomatosis, or peritoneal mesothelioma should be pursued.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Digestive System Surgical Procedures / methods. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / surgery. Pseudomyxoma Peritonei / drug therapy. Pseudomyxoma Peritonei / surgery
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Female. Fluorouracil / administration & dosage. Humans. Injections, Intraperitoneal. Male. Middle Aged. Mitomycin / administration & dosage. Multivariate Analysis. Probability. Proportional Hazards Models. Retrospective Studies. Survival Analysis. Syndrome

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright Harcourt Publishers Limited.
  • (PMID = 11373099.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


8. Patel NP, Taylor CA, Levine EA, Trupiano JK, Geisinger KR: Cytomorphologic features of primary peritoneal mesothelioma in effusion, washing, and fine-needle aspiration biopsy specimens: examination of 49 cases at one institution, including post-intraperitoneal hyperthermic chemotherapy findings. Am J Clin Pathol; 2007 Sep;128(3):414-22
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytomorphologic features of primary peritoneal mesothelioma in effusion, washing, and fine-needle aspiration biopsy specimens: examination of 49 cases at one institution, including post-intraperitoneal hyperthermic chemotherapy findings.
  • Primary peritoneal mesotheliomas (PPMs) are rare tumors of adults.
  • At our institution, PPMs are treated with a combination of cytoreductive surgery and intraperitoneal hyperthermic chemotherapy (IPHC) in appropriate patients.
  • Of the corresponding 49 PPM histologic specimens, 46 were epithelial, 2 sarcomatoid, and 1 multicystic mesothelioma.
  • This includes our experience with washing specimens obtained from patients with PPM following treatment with cytoreductive surgery combined with IPHC.
  • [MeSH-major] Ascitic Fluid / pathology. Mesothelioma / pathology. Peritoneal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17709315.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Franklin WA: Diagnosis of lung cancer: pathology of invasive and preinvasive neoplasia. Chest; 2000 Apr;117(4 Suppl 1):80S-89S
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The histopathologic appearance of lung carcinoma remains an important guide to prognosis and treatment.
  • The newly revised World Health Organization classification retains the broadest pathologic categories of the older classification but includes several revisions, including the elimination of the small cell, intermediate cell type category; the addition of large cell neuroendocrine and spindle/giant cell categories; and an extended consideration of preneoplastic lesions.
  • The significance of expression of neuroendocrine markers, histologic grading of response to chemotherapy, and delineation of morphologic changes preceding the occurrence of invasive carcinoma are all areas where understanding microscopic cellular changes in the airways will be critical for clinical advance.
  • [MeSH-minor] Algorithms. Diagnosis, Differential. Humans. Mesothelioma / pathology. Neoplasm Invasiveness. Neuroendocrine Tumors / pathology. Precancerous Conditions / pathology. World Health Organization

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10777460.001).
  • [ISSN] 0012-3692
  • [Journal-full-title] Chest
  • [ISO-abbreviation] Chest
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Number-of-references] 24
  •  go-up   go-down


10. Burlando B, Ranzato E, Volante A, Appendino G, Pollastro F, Verotta L: Antiproliferative effects on tumour cells and promotion of keratinocyte wound healing by different lichen compounds. Planta Med; 2009 May;75(6):607-13
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Five compounds representative of major structural classes of lichen polyketides, VIZ. (+)-usnic (1), salazinic (2), vulpinic (3), gyrophoric (4), and evernic acids (5), were investigated for their ability to affect cell proliferation or wound healing, two functional targets of relevance for research on cancer or tissue regeneration.
  • The experiments were carried out on MM98 malignant mesothelioma cells, A431 vulvar carcinoma cells, and HaCaT keratinocytes.
  • The NRU and CV cytotoxicity assays showed high toxicity for (+)-usnic acid, intermediate toxicity for vulpinic acid, and low toxicity for salazinic, gyrophoric and evernic acids.
  • Scratch wounding experiments on HaCaT monolayers, in the presence of subtoxic doses of lichen compounds, showed strong wound closure effects by (+)-usnic and gyrophoric acid, an intermediate effect by vulpinic and salazinic acids, and no effect by evernic acid.
  • In conclusion, (+)-usnic acid might be a particularly interesting compound for the prevention of hyperproliferation syndromes, while (+)-usnic and gyrophoric acids qualify as interesting leads in the promotion of tissue regeneration.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / pharmacology. Cell Proliferation / drug effects. Keratinocytes / drug effects. Lichens / chemistry. Plant Extracts / pharmacology. Wound Healing / drug effects
  • [MeSH-minor] Benzoates / pharmacology. Benzoates / therapeutic use. Benzofurans / pharmacology. Benzofurans / therapeutic use. Cell Line, Tumor. Female. Furans / pharmacology. Furans / therapeutic use. Humans. Hydroxybenzoates / pharmacology. Hydroxybenzoates / therapeutic use. Lactones / pharmacology. Lactones / therapeutic use. Neoplasms / drug therapy. Phenylacetates / pharmacology. Phenylacetates / therapeutic use. Phytotherapy. Salicylates / pharmacology. Salicylates / therapeutic use

  • Hazardous Substances Data Bank. USNIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright Georg Thieme Verlag KG Stuttgart. New York.
  • (PMID = 19199230.001).
  • [ISSN] 1439-0221
  • [Journal-full-title] Planta medica
  • [ISO-abbreviation] Planta Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Benzoates; 0 / Benzofurans; 0 / Furans; 0 / Hydroxybenzoates; 0 / Lactones; 0 / Phenylacetates; 0 / Plant Extracts; 0 / Salicylates; 0 / salazinic acid; 0W584PFJ77 / usnic acid; 537-09-7 / evernic acid; 548-89-0 / gyrophoric acid; 73622-57-8 / vulpinic acid
  •  go-up   go-down


11. Szöllósi A, Ferenc C, Pintér T, Erényi A, Nagy A: [Benign cystic mesothelioma, a rare tumor of the peritoneum]. Magy Seb; 2005 Feb;58(1):35-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Benign cystic mesothelioma, a rare tumor of the peritoneum].
  • [Transliterated title] Benignus cisztikus mesothelioma, a peritoneum ritka daganata.
  • Appendicetomy was performed, during the operation multiple cystic lesions were discovered on the right ovary and the peritoneal surface of the mesentery.
  • Laparatomy was performed with removal of the visible cystic lesions, which contained mucous fluid.
  • Final histology revealed benign cystic mesothelioma, which is a rare lesion of the peritoneum, occurring mainly in women in reproductive age.
  • The etiology of cystic mesothelioma is still unclear.
  • Some authors reported effective intraperitoneal chemotherapy, but no clinical study is available about long term outcome.
  • [MeSH-major] Mesothelioma, Cystic. Peritoneal Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16018599.001).
  • [ISSN] 0025-0295
  • [Journal-full-title] Magyar sebészet
  • [ISO-abbreviation] Magy Seb
  • [Language] hun
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


12. Lockhart AC, Bukowski R, Rothenberg ML, Wang KK, Cooper W, Grover J, Appleman L, Mayer PR, Shapiro M, Zhu AX: Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumors. Cancer Chemother Pharmacol; 2007 Jul;60(2):203-9
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Key eligibility criteria included adult subjects with refractory solid tumors or solid tumors for which conventional therapy was unsuitable or did not exist, good performance status (ECOG ( 2), and adequate hematologic, hepatic, and renal functions.
  • Plasma pharmacokinetic (PK) sampling was performed during the first cycle of therapy.
  • Two subjects developed dose-limiting toxicities (DLTs) at 75 mg/m(2); one subject with grade 3 and one subject with grade 4 neutropenia with fever.
  • Three subjects treated at an intermediate dose level of 60 mg/m(2) had no DLTs.
  • MAC-321 was rapidly absorbed with a mean C (max) value of less than 1 h.
  • Disease stabilization was seen in four subjects with the following tumors: mesothelioma (14 cycles), chondrosarcoma (12 cycles), small cell carcinoma (10 cycles), and prostate carcinoma (6 cycles).
  • Four subjects had disease stabilization.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Neoplasms / drug therapy. Paclitaxel / analogs & derivatives
  • [MeSH-minor] Administration, Oral. Adult. Aged. Area Under Curve. Biological Availability. Dose-Response Relationship, Drug. Female. Fever / chemically induced. Half-Life. Humans. Male. Middle Aged. Neutropenia / chemically induced. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17091249.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / MAC321; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


13. Santhanam S, Decatris M, O'Byrne K: Potential of interferon-alpha in solid tumours: part 2. BioDrugs; 2002;16(5):349-72
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The second part of this review examines the use of recombinant interferon-alpha (rIFNalpha) in the following solid tumours: superficial bladder cancer, Kaposi's sarcoma, head and neck cancer, gastrointestinal cancers, lung cancer, mesothelioma and ovarian, breast and cervical malignancies.
  • In superficial bladder cancer, intravesical rIFNalpha has a promising role as second-line therapy in patients resistant or intolerant to intravesical bacille Calmette-Guérin (BCG).
  • In HIV-associated Kaposi's sarcoma, rIFNalpha is active as monotherapy and in combination with antiretroviral agents, especially in patients with CD4 counts >200/mm(3), no prior opportunistic infections and nonvisceral disease. rIFNalpha has shown encouraging results when used in combination with retinoids in the chemoprevention of head and neck squamous cell cancers.
  • In neuroendocrine tumours, including carcinoid tumour, low-dosage (</=3 MU) or intermediate-dosage (5 to 10 MU) rIFNalpha is indicated as second-line treatment, either with octreotide or alone in patients resistant to somatostatin analogues.
  • Intracavitary IFNalpha may be useful in malignant pleural effusions from mesothelioma.
  • Similarly, intraperitoneal IFNalpha may have a role in the treatment of minimal residual disease in ovarian cancer.
  • In breast cancer, the only possible role for IFNalpha appears to be intralesional administration for resistant disease.
  • IFNalpha may have a role as a radiosensitising agent for the treatment of cervical cancer; however, this requires confirmation in randomised trials.
  • On the basis of current evidence, the routine use of rIFNalpha is not recommended in the therapy of head and neck squamous cell cancers, upper gastrointestinal tract, colorectal and lung cancers, or mesothelioma.
  • Further data from randomised studies in solid tumours are needed where rIFNalpha has activity, such as neuroendocrine tumours, minimal residual disease in ovarian cancer, and cervical cancer.
  • Studies of IFNalpha-stimulated gene expression, which are now feasible, should help to identify molecular predictors of response and allow us to target therapy more selectively to patients with solid tumours responsive to IFNalpha.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Interferon-alpha / therapeutic use. Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12408739.001).
  • [ISSN] 1173-8804
  • [Journal-full-title] BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
  • [ISO-abbreviation] BioDrugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha
  • [Number-of-references] 391
  •  go-up   go-down






Advertisement